News
People lost more weight on Zepbound
Digest more
Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
We came across a bullish thesis on Eli Lilly and Company (LLY ... driven largely by the runaway success of its GLP-1-based treatments, Mounjaro and Zepbound. These two drugs alone are ...
Eli Lilly launched a couple of new successful drugs, Mounjaro and Zepbound, that have boosted ... In 2021, Pfizer's COVID-19 vaccine success had many wondering how to invest in Pfizer.
Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...
Eli Lilly's stock dropped by 10.14% even though the company reported strong earnings for the first quarter. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback